Regrettably, we had to cancel our Aptamers 2020 meeting in April due to the COVID19 pandemic. We provisionally scheduled a later version of this meeting originally on 16th and 17th September 2020. However, due to the ongoing circumstances, and considering that air travel may still not be possible by September, we are keeping our options...Read More

EDITORIAL ISSN: 0000-0000 EJEV (2020), Vol 1, 1-2 Published online: 01 April 2020 Full Text (Sohail ~209kb) Muhammad Sohail* St Hilda’s College, Cowley Place, University of Oxford, Oxford OX4 1DY, UK *Correspondence to: Muhammad Sohail, Email: muhammad.sohail@st-hildas.ox.ac.uk © Copyright The Author(s). This is an open access article, published under the terms of the Creative Commons Attribution...Read More

METHOD ISSN: 2514-3247 Aptamers (2019), Vol 3, 10-16 Published online: 20 December 2019 Full Text Access Zhesen Tan, Trevor A Feagin, Jennifer M Heemstra* Department of Chemistry, Emory University, Atlanta, Georgia, USA *Correspondence to: Jennifer Heemstra, Email: jen.heemstra@emory.edu, Tel: + 404 727 7766 Received: 15 June 2019 | Revised: 05 December 2019 | Accepted: 06 December 2019 ©...Read More

TECHNICAL REPORT ISSN: 2514-3247 Aptamers (2019), Vol 3, 04-09 Published online: 23 November 2019 Full Text Access Justin Henri 1, Narges Bayat 3, 4, Joanna Macdonald 1, 2, and Sarah Shigdar 1,2,* 1 School of Medicine Deakin University, Geelong, Victoria 3128, Australia 2 Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria, 3216, Australia 3...Read More

We are delighted and honoured that Professor Larry Gold will deliver a keynote address at Aptamers 2020. He will also receive a Lifetime Achievement Award on behalf of the International Society on Aptamers (INSOAP) for is pioneering and extraordinary contributions to the field of aptamers and therapeutics. Dr Larry Gold is the Founder and Chairman...Read More

We are delighted to announce that Dr Nebojsa Janjic will chair Aptamers 2020. Dr Nebojsa Janjic is the Chief Science Officer at SomaLogic. Prior to joining SomaLogic, Dr Janjic was the CSO at Replidyne, Inc, a biotechnology company focusing on the development of small-molecule antibacterial agents. Prior to Replidyne, he was Senior Director of Drug Discovery...Read More

MEETING REVIEW ISSN: 2514-3247 Aptamers (2019), Vol 3, 01-03 Published online: 14 July 2019 Full Text Access Sarah Shigdar 1,2, Philip Johnson 3, Georg Pietruschka 4, Tjaša Legen 4, Günter Mayer 4, Maureen McKeague 5,6 1 School of Medicine Deakin University, Geelong, Victoria 3128, Australia 2 Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria...Read More

The INSOAP’s Aptamers meeting has been running at Oxford since 2014, and has attracted attendance from several key scientists in the field, industry researchers, solution providers, and young and emerging researchers. We are now inviting proposals for chairing the 2020 meeting. If you are interested in chairing it, or would like to suggest a chair,...Read More

Fee Structure Early bird and group discounts are available. Register 3 for the price of 2 until 31 December 2019 (cheapest registration free – Promocode: 3for2)* Register 4 for the price of 3 any time (cheapest registration free – Promocode: 4for3)* Fees apply to payments made on or before the indicated deadlines and not to...Read More

TAGCyx Biotechnologies Inc. is a drug discovery and development company based in Japan, spun out of Riken Research Institute. We utilizes its proprietary, artificial nucleotide base pair technology invented by Dr. Ichiro Hirao to generate unique DNA aptamer, Xenoligo®, for therapeutic purposes.  Amongst various type of aptamers, the advantage of Xenoligo® are: 1) comprised of DNA,...Read More